Ribociclib plus letrozole alters the immune subset composition in older (≥70 yrs.) patients with HR+/HER2-metastatic breast cancer

被引：0
|
作者：
Lambrechts, Yentl
Hatse, Sigrid
Kenis, Cindy
Decoster, Lore
de Azambuja, Evandro
Jerusalem, Guy
Neven, Patrick
Dal Lago, Lissandra
Denys, Hannelore
Vuylsteke, Peter
Cornelis, Frank
Punie, Kevin
Floris, Giuseppe
Desmedt, Christine
Laenen, Annouschka
Ponde, Noam
Wildiers, Hans
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 05期
关键词：
D O I：
10.1158/1538-7445.SABCS22-P4-01-29
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P4-01-29
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Ribociclib in HR+/HER2-Advanced or Metastatic Breast Cancer Patients
    Rascon, Kaitlin
    Flajc, Goran
    De Angelis, Carmine
    Liu, Xinli
    Trivedi, Meghana V.
    Ekinci, Ekim
    ANNALS OF PHARMACOTHERAPY, 2019, 53 (05) : 501 - 509
  • [2] Abemaciclib in HR+/HER2-metastatic breast cancer: A realworld experience
    Bottosso, M.
    Giarratano, T.
    Barbieri, C.
    Menichetti, A.
    Cumerlato, E.
    Miglietta, F.
    Genovesi, E.
    Amato, O.
    Dieci, M. V.
    Griguolo, G.
    Guarneri, V.
    ANNALS OF ONCOLOGY, 2021, 32 : S73 - S74
  • [3] Cost of recurrence among patients with HR+/HER2-metastatic breast cancer.
    Engel-Nitz, Nicole M.
    Becker, Laura
    Gerdes, Randall
    Hao, Yanni
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [4] Validation of Claims Algorithm to Identify HR+/HER2-Metastatic Breast Cancer Patients
    Chin, Andi
    Wu, Xiyuan
    Ip, Queeny
    Lyle, Derek
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2024, 33 : 620 - 620
  • [5] Ribociclib Improves Overall Survival in HR+/HER2-Metastatic Breast Cancer Across Common Genomic and Clinical Subtypes
    Jacobson, Anne
    ONCOLOGIST, 2022, 27 (SUPPL 1): : S11 - S12
  • [6] Ribociclib Improves Overall Survival in HR+/HER2-Metastatic Breast Cancer Across Common Genomic and Clinical Subtypes
    Jacobson, Anne
    ONCOLOGIST, 2022, 27 : S11 - S12
  • [7] Clinical outcomes among HR+/HER2-metastatic breast cancer patients with multiple metastatic sites
    Xie, J.
    Hao, Y.
    Li, N.
    Lin, P. L.
    Ohashi, E.
    Koo, V.
    Wu, E. Q.
    CANCER RESEARCH, 2016, 76
  • [8] Experience with eribulin in HR+/HER2-metastatic breast cancer, including a male
    Munoz Sanchez, Maria del Mar
    Soriano Rodriguez, Maria del Carmen
    Molina Garrido, Maria Jose
    Lopez-Gonzalez, Ana
    Garcia-Palomo, Andres
    Lopez-Gonzalez, Laura
    Plata Fernandez, Maria Yessica
    Luque Caro, Natalia
    Sanchez Rovira, Pedro
    FUTURE ONCOLOGY, 2018, 14 (07) : 5 - 12
  • [9] Sacituzumab govitecan in HR+ and HER2-metastatic breast cancer: for all or for some?
    Loibl, Sibylle
    Holtschmidt, Johannes
    LANCET, 2023, 402 (10411): : 1394 - 1395
  • [10] Physician survey in the treatment of HR+/HER2-metastatic breast cancer in Egypt
    Aboelkheir, E.
    Ashour, A.
    Fadel, S.
    Arafat, W.
    BREAST, 2021, 56 : S31 - S31
12345